Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1

Status

Completed 44Terminated 5Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Breast Neoplasms 8Neoplasm Metastasis 7Multiple Myeloma 6Prostatic Neoplasms 5Pain 3Uterine Cervical Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Bone Neoplasms 2Uterine Cervical Dysplasia 1Urologic Neoplasms 1Small Cell Lung Carcinoma 1Precancerous Conditions 1Pleural Effusion, Malignant 1Osteoporosis 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm, Residual 1Lung Neoplasms 1Kidney Neoplasms 1Humoral Hypercalcemia Of Malignancy 1Hematologic Neoplasms 1Giant Cell Tumors of Bone 1Giant Cell Tumor of Bone 1Disease Progression 1Carcinoma, Ductal, Breast 1Breast Neoplasms, Male 1Bone Diseases, Metabolic 1Adenocarcinoma 1

Interventions

Docetaxel 56Prednisone 36enzalutamide 25Leuprolide 24Magnetic Resonance Spectroscopy 19Abiraterone Acetate 19bicalutamide 17Radiotherapy 15Goserelin 15abiraterone 12acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11olaparib 9Androgen Antagonists 9gallium 68 PSMA-11 8cabazitaxel 8Radiotherapy, Intensity-Modulated 8Metformin 8Ketoconazole 8Gonadotropin-Releasing Hormone 8Cyclophosphamide 8apalutamide 7Doxorubicin 7luprolide acetate gel depot 6cabozantinib 6Radiosurgery 6Estramustine 6Dexamethasone 6Calcitriol 6Biopsy 6pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Prostatic Neoplasms × Zoledronic Acid × Clear all
NCT00058188 2020-12-08

Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation

Northwestern University

Phase 3 Terminated
53 enrolled
Genitourinary

Osteoporosis, Prostatic Neoplasms

NCT00005073 2013-05-01

Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms

Novartis

Phase 3 Terminated
544 enrolled
Genitourinary

Prostatic Neoplasms

NCT00294437 2012-05-01

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

Central European Cooperative Oncology Group

Phase 3 Terminated
376 enrolled
Genitourinary

Prostatic Neoplasms

NCT00258765 2010-04-26

Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.

Novartis

Phase 2 Terminated
1 enrolled
Genitourinary

Prostatic Neoplasms

NCT00391950 2009-11-23

Maintaining Bone Strength in Men With Prostate Cancer

Novartis

Phase 3 Terminated
300 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡